Broadwing Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $9.9M

  • Investors
  • 3

Broadwing Bio General Information

Description

Operator of a biotechnology company intended to develop targeted antibody therapies for the treatment of ophthalmic diseases. The company's operations mainly involve conducting programs directed to genetically validated ophthalmology targets using antibody discovery technologies, enabling patients to receive effective eye treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 300
  • San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 300
  • San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Broadwing Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 02-Feb-2024 $9.9M Completed Pre-Clinical Trials
1. Joint Venture 07-Dec-2020 Completed Pre-Clinical Trials
To view Broadwing Bio’s complete valuation and funding history, request access »

Broadwing Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-3
Series A-2
Series A-1 16,100,806 $0.000001 $0.29 $0.29 1x $0.29 31.19%
To view Broadwing Bio’s complete cap table history, request access »

Broadwing Bio Patents

Broadwing Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024227154-A1 Complement component 3 (c3)-specific antibodies and uses thereof Inactive 28-Apr-2023
AU-2023259251-A1 Angiopoietin-related protein 7-specific antibodies and uses thereof Pending 29-Apr-2022
EP-4514470-A1 Angiopoietin-related protein 7-specific antibodies and uses thereof Pending 29-Apr-2022
US-20250296996-A1 Angiopoietin-related protein 7-specific antibodies and uses thereof Pending 29-Apr-2022
WO-2023212294-A1 Angiopoietin-related protein 7-specific antibodies and uses thereof Inactive 29-Apr-2022 C07K16/22
To view Broadwing Bio’s complete patent history, request access »

Broadwing Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Broadwing Bio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Echo Investment Capital PE/Buyout Minority
Alloy Therapeutics VC-Backed Company Majority
Maze Therapeutics Corporation Majority
To view Broadwing Bio’s complete investors history, request access »

Broadwing Bio FAQs

  • When was Broadwing Bio founded?

    Broadwing Bio was founded in 2020.

  • Where is Broadwing Bio headquartered?

    Broadwing Bio is headquartered in San Francisco, CA.

  • What is the size of Broadwing Bio?

    Broadwing Bio has 3 total employees.

  • What industry is Broadwing Bio in?

    Broadwing Bio’s primary industry is Biotechnology.

  • Is Broadwing Bio a private or public company?

    Broadwing Bio is a Private company.

  • What is the current valuation of Broadwing Bio?

    The current valuation of Broadwing Bio is .

  • What is Broadwing Bio’s current revenue?

    The current revenue for Broadwing Bio is .

  • How much funding has Broadwing Bio raised over time?

    Broadwing Bio has raised $9.9M.

  • Who are Broadwing Bio’s investors?

    Echo Investment Capital, Alloy Therapeutics, and Maze Therapeutics have invested in Broadwing Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process